Role of PCSK9 inhibitors in the management of dyslipidaemia
No Thumbnail Available
Date
2024-03
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Proprotein convertase subtilisin kexin9 (PCSK9) inhibitors are novel agents that lower LDL cholesterol and reduce cardio-vascular event rate. Being expensive, these agents are reserved for those with high risk or very high risk of CV events and with suboptimal response to statins and ezetimibe, with or without bempedoic acid or those intolerant to statins.
Description
Keywords
PCSK9 inhibitors, Dyslipidaemia, LDL, Familial hyperlipidemia
Citation
Nair Tiny . Role of PCSK9 inhibitors in the management of dyslipidaemia. Indian Heart Journal. 2024 Mar; 76(1): 44-50